Logo
x

Search

Subscribe Now

Acadia Pharmaceuticals

Acadia Pharmaceuticals Reports P-III (ADVANCE-2) Study Results of Pimavanserin to Treat Negative Schizophrenia Symptoms

Acadia Pharmaceuticals Reports P-III (ADVANCE-2) Study Results of Pimavanserin to Treat Negative Schizophrenia Symptoms

  • March 13, 2024
Acadia Pharmaceuticals Reports P-III Study (LAVENDER) Results of Daybue (trofinetide) for the Treatment of Rett Syndrome

Acadia Pharmaceuticals Reports P-III Study (LAVENDER) Results of Daybue (trofinetide) for the Treatment of Rett Syndrome

  • June 10, 2023
Acadia Pharmaceuticals Launches Daybue (trofinetide) for the Treatment of Rett Syndrome in the US

Acadia Pharmaceuticals Launches Daybue (trofinetide) for the Treatment of Rett Syndrome in the US

  • April 18, 2023
Acadia’s Daybue (trofinetide) Receives the US FDA’s Approval for Rett Syndrome in Adult and Pediatric Patients Aged ≥2Years

Acadia’s Daybue (trofinetide) Receives the US FDA’s Approval for Rett Syndrome in Adult and Pediatric Patients Aged ≥2Years

  • March 13, 2023
Top 20 Biopharma M&A of 2020 by Total Deal Value

Top 20 Biopharma M&A of 2020 by Total Deal Value

  • January 7, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.